Figure 3.

Effect of AKB-9778 on IOP and outflow facility in ocular normotensive mice. (A) Change in pretreatment IOP (mean ± standard error, n = 14) by comparing pretreatment (day 0) with treatment (placebo or AKB-9778). IOP was measured once per day for 3 consecutive days prior to dosing. (B) Time course of IOP lowering after eyes received third daily treatment. Zero hour indicates pretreatment IOP on day 3 (central bar indicates median, the plus sign indicates mean, the range shows minimum to maximum, n = 5) with the additional IOP collections at 2 and 4 hours post eye drop administration. (C) Outflow facility (central bar is median, the range shows minimum to maximum, individual data points are indicated, n = 9) of eyes treated with AKB-9778 for 3 days (*P ≤ 0.05, **P ≤ 0.01), comparing drug to placebo-treated contralateral eyes.